HIV and pregnancy: Is the outlook for mother and baby transformed?

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 6, 2004, Pages 471-475

  Semprini, Augusto E ^a,b   Fiore, Simona ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE   (Italy)

Author keywords

Breastfeeding; Highly active antiretroviral therapy; HIV; Vertical transmission

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; ZIDOVUDINE;

ANEMIA; BREAST FEEDING; CESAREAN SECTION; DELIVERY; DRUG EFFICACY; ECLAMPSIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LYMPHOCYTE COUNT; PATIENT COUNSELING; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRENATAL DRUG EXPOSURE; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; SOLUTIO PLACENTAE; TERATOGENICITY; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS REPLICATION; DISEASE TRANSMISSION; FEMALE; NEWBORN; PREGNANCY COMPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BREAST FEEDING; CESAREAN SECTION; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 16644388518     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200412000-00006     Document Type: Review

References (40)

1. UNAIDS. Report on the global AIDS epidemic. Executive summary; 2004.
2. Centers for Disease Control and Prevention. Current trends recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1985; 34:721-726.
3. Kass NE. Policy, ethics and reproductive choice: pregnancy and childbearing among HIV infected women. Acta Paediatr Suppl 1994; 400:95-98.
4. Thorne C, Newell ML. Prevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis 2004; 17:247-252. This review addresses HIV MTCT risk factors including maternal viraemia, mode of delivery, breastfeeding and infant gender. It discusses the use of interventions to reduce vertical transmission in different settings and the effectiveness of short prophylactic antiretroviral regimens.
5. Thornton A, Romanelli F, Collins JD. Reproduction decision making for couples affected by HIV: a review of the literature. Top HIV Med 2004; 12:61-67. This review is the result of a literature search performed to identify information to counsel couples infected with HIV.
6. Gilling-Smith C, Smith JR, Semprini AE. HIV and infertility: time to treat. There's no justification for denying treatment to parents who are HIV positive. BMJ 2001; 322:566-567.
7. Semprini A, Fiore S. HIV and reproduction. Curr Opin Obstet Gynecol 2004; 16:257-262. This review addresses how semen washing, reproductive technology, antiretroviral therapy and obstetrical care can work in sequence to allow safe reproduction in couples infected with HIV.
8. Campbell T, Bernhardt S. Factors that contribute to women declining antenatal HIV testing. Health Care Women Int 2003; 24:544-551
9. Gallant JE. HIV counseling, testing, and referral. Am Fam Physician 2004; 70:295-302.
10. Newell ML, Rogers M, editors. Pregnancy and HIV infection: a European consensus on management. AIDS 2002; 16 (Suppl 2).
11. Peters V, Liu KL, Dominguez K, et al. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort. Pediatrics 2003; 111 (5 Pt 2):1186-1191.
12. Centers for Disease Control and Prevention. Reducing HIV transmission from mother-to-child: an opt-out approach to HIV screening. http://www.cdc.gov [Accessed 5 September 2004]
13. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Mother-Infant Rapid Intervention At Delivery (MIRIAD) Study Group. Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004; 292:219-223. This paper shows rapid HIV testing as a feasible, accurate and timely test for women in labour, providing prompt access to intrapartum and neonatal antiretroviral prophylaxis.
14. Minkoff H, Ahdieh L, Watts H, et al. The relationship of pregnancy to the use of highly active antiretroviral therapy. Am J Obstet Gynecol 2001; 184:1221-1227.
15. Centers for Disease Control and Prevention. Recommendations for the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994; 43:1-27.
16. Lyons F, Coughlan S, Byrne C, et al. Emergence of genotypic resistance in HIV-1-infected pregnant women taking HAART to reduce mother-to-child transmission of HIV-1. 11th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2004; San Francisco, CA, 2004. http://www. retroconference.org [Accessed 21 September 2004]
17. Coovadia H. Antiretroviral agents: how best to protect infants from HIV and save their mothers from AIDS. N Engl J Med 2004; 351:289-292.
18. Sullivan JL. Prevention to mother-to-child transmission of HIV - what next? J Acquir Immune Defic Syndr 2003; 34 (Suppl 1):S67-S72. This review addresses available interventions and future options to reduce MTCT.
19. Public Health Service Taskforce. Safety and toxicity of individual antritetroviral agents in pregnancy. http://AIDSinfo.nih.gov [Accessed 5 August 2004]
20. Covington DL, Conner SD, Doi PA, et al. Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet Gynecol 2004; 103:1181-1189.
21. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry interim report for 1 January 1989 to 31 January 2004. http:// www.apregistry.com/who.htm [Accessed 5 August 2004]
22. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[(2-phosphonomethoxy) propyl] adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48:1469-1487.
23. European Collaborative Study. The Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14:2913-2920.
24. Watts DH, Balasubramanian R, Maupin RT, et al. Maternal toxicity and pregnancy complications in HIV-infected women receiving antiretroviral therapy: an analysis of the PACTG 316 study. Am J Obstet Gynecol 2004; 190:506-516. This paper describes maternal complications occurring in women enrolled in a perinatal trial in the era of HAART.
25. By A Suy, O Coll, E Martinez, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy [abstract]. The XV International AIDS Conference; 11-16 July 2004; Bangkok, Thailand. Bologna, Italy: Medimond srl. Authors report their recent data on an increasing number of cases of preeclampsia and fetal death in HIV-infected pregnant women receiving HAART.
26. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053-2061.
27. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr 2003; 32:292-297.
28. Bauer GH, Welles SL, Colgrove RR, Pitt J; Women and Infants Transmission Study Team. Zidovudine resistance phenotype and risk of perinatal HIV-1 transmission in zidovudine monotherapy-treated mothers with moderately advanced disease. J Acquir Immune Defic Syndr 2003; 34:312-319.
29. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy 2004; 351:229-240.
30. The International Perinatal HIV Group. Mode of delivery and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies. N Engl J Med 1999; 340:977-987.
31. Dominguez KL, Lindegren ML, D'Almada PJ, et al. Increasing trend of cesarean deliveries in HIV-infected women in the United States from 1994 to 2000. J Acquir Immune Defic Syndr 2003; 33:232-238.
32. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J Infect Dis 2001; 183:539-545.
33. European Collaborative Study. Are girls more at risk of intra-uterine-acquired HIV infection than boys? AIDS 2004; 18:344-347.
34. Fiore J, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17:2169-2176.
35. Tuomala R, O'Driscoll PT, Bremer J, et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 2003; 187:375-384. An important paper on risk factors for MTCT in the HAART era.
36. European HIV in Obstetrics Group. Higher rates of post-partum complications in HIV infected than in uninfected women irrespective of mode of delivery. AIDS 2004; 18:933-938. This paper looks at postpartum complications after vaginal delivery as well as elective Caesarean delivery, and shows that HIV-infected women are at increased risk of postpartum complications regardless of mode of delivery, but that modification of clinical practice, particularly use of prophylactic antibiotics, would reduce this risk.
37. Coutsoudis A, Dabis F, Fawzi S, et al. Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breastfed children: an individual patient data meta-analysis. J Infect Dis 2004; 189:2154-2166.
38. Willumsen JF, Filteau SM, Coutsoudis A, et al. Breastmilk RNA viral load in HIV-infected South African women: effects of subclinical mastitis and infant feeding. AIDS 2003; 17:407-414.
39. Shetty AK. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2003; 34:482-490.
40. Vyankandondera J, Luchters S, Hassink E, et al. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA) [abstract]. 2nd IAS Conference on HIV Pathogenesis and Treatment; 13-16 July 2003; Paris. http://IAS.se [Accessed 21 September 2004] Preliminary results from this first trial to address antiretroviral therapy to prevent postnatal transmission of HIV.